You don't need to reply to me, but I definitely would want another pcr.
Tests can mess up.
What have you got to lose?
OH
Anne & Advocate -- Thanks so much for your support. There is something called the "Gold Standard", which means they do double check, BUT I am not sure if that applies to this particular test. I will ask and see if I can find out. But at week 15, I'm more concerned with what happens from here on out, so we'll see.
Thanks again,
Bee
Hector -- Yes, a horrible shock because I felt I was clear with the person I asked for my numbers (which came back after my appt). I do have supportive people in my life, but was too in shock to share this until I got a better understanding of it myself.
"These analyses showed that 4-week lead-in response helped predict SVR..."
Thank you for the studies Hector! It helps.
Can Do Man -- Good to know your experience in this too. Thanks for the great info.! "There are at least a few people here who have SVRd and reported a blip at or after week 12 and you have no way of knowing if this is one or not..."
Frijole -- Thanks. The confusion was with the person I spoke to, who must have misunderstood what I was asking. From here on out, I will have the labs in my little hands before I go celebrating. I know about the different sensitivity tests. I am going to ask for a QuantaSure test, for sure on the next labs. As for re-running the 12 weeks.....at this point.......I'm guessing they may have already done that, but even if not, I am more interested in my next labs anyway.
Flcyclist -- No, it wasn't a misinterpretation on the numbers, I think it was a misunderstanding in my question of -- Am I still UND at 12 weeks (which sounded like a pretty clear question to me, but there you have it). My 8 week says: Not detected; my 12 week says: <43 Detected. Thanks so much
Suezee -- Thank you for your support :) I think you may be right. Because of ancestry, we are in the same boat.
Indy, Starshine -- Amen, amen!! Thank you so much for the prayers :)
Sandy, Screaming, Keith, Belle -- Your support and kindness are truly wonderful. Thank you.
Willy -- Prior to tx, I was Vitamin D deficient, so I am on supplements for that. Thanks :)
Dave -- This helps me, so thank you so much. "My trial doctor did not consider that a breakthrough. He said a real break through would mean that my VL had climbed several hundred or more."
Billy -- Thank you for your kind words. I do feel the love here :)
Will -- I will be going for labs now every week (becoming quite the pincushion), so we'll see what happens from here on out.
Thanks everyone for being in my corner. It has been a difficult few days. I have faith I will make it through this. Given the data and encouragement you have given me, I feel even better about that. Bee Blessed........
I hope your doctor will re-run the test or use a more sensitive test. Best wishes for UND.
Advocate1955
I agree that you should retest and hopefully it was a glitch. It all sounds too iffy to me. Best of luck and we'll all cross our fingers for you.
This is the labcorp test used in the Victrelis trials. I don't understand why your doctor is not using something more sensitive quantifiable to 43. Hopefully the procrit will allow you to take more ribavirin when it kicks in.
Hepatitis C Virus (HCV), Quantitative, Real-time PCR (Graphical)
HCV RNA Quantitation, TaqMan®
Test Number: 550070
"The limit of detection of this assay is 7.1 IU/mL for HCV genotype 1, and the quantifiable range of the assay is 25 IU/mL to 69,000,000 IU/mL."
"BERLIN, March 31, 2011 - Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced results from several new data analyses from the pivotal Phase III studies evaluating the addition of its investigational oral protease inhibitor VICTRELIS™ (boceprevir) to peginterferon alfa-2b and ribavirin (PR) in adult patients with chronic hepatitis C virus (HCV) genotype 1 infection. The new data analyses identified potential predictors for the likelihood of achieving sustained virologic response (SVR)¹ based on a patient's response during a four-week lead-in period with PR alone prior to the addition of VICTRELIS, as well as the genetic marker IL28B. The results were presented today at The International Liver Congress™ / 46th European Association for the Study of the Liver (EASL) annual meeting. "
"HCV-RNA decline after 4-week PR lead-in period helped predict likelihood of SVR
In pre-specified analyses, researchers evaluated the relationship between decline in levels of virus (HCV-RNA) after the 4-week PR lead-in period to overall SVR.
In the HCV SPRINT-2 treatment-naïve study, patients receiving VICTRELIS who had good response after the 4-week lead-in period, defined by a greater than or equal to 1.0-log10 decline in HCV-RNA , achieved SVR rates of 81 percent (203/252) in the RGT arm and 79 percent (200/254) in the 48-week treatment arm compared to 51 percent (133/260) in the PR control arm. Patients with poor response after the 4-week lead-in, defined by a less than 1.0-log10 decline in HCV-RNA, achieved SVR rates of 28 percent (27/97) in the RGT arm and 38 percent (36/95) in the 48-week treatment arm compared to 4 percent (3/83) in the PR control arm.
Similarly, in the HCV RESPOND-2 treatment-failure study, patients receiving VICTRELIS who had good response after the lead-in achieved SVR rates of 73 percent (80/110) in the RGT arm and 79 percent (90/114) in the 48-week treatment arm compared to 25 percent (17/67) in the PR control arm. Patients with poor response after the 4-week lead-in achieved SVR rates of 33 percent (15/46) in the RGT arm and 34 percent (15/44) in the 48-week treatment arm compared to 0 percent (0/12) in the PR control arm.
These analyses showed that 4-week lead-in response helped predict SVR in all three treatment groups, and the addition of VICTRELIS to the treatment regimen improved SVR rates regardless of whether patients had good or poor response during the lead-in period. "
....................
"Data on resistance-associated variants also presented
To better understand resistance-associated variants when VICTRELIS was added to standard therapy, researchers analyzed blood samples from 343 patients who did not achieve SVR in the HCV SPRINT-2 and HCV RESPOND-2 studies. Samples were obtained at various time points of virologic failure (BREAKTHROUGH, incomplete virologic response, relapse and nonresponse), and resistance-associated variants were detected by population sequencing.
Results of this analysis [Oral presentation Parallel Session: HCV Therapy] showed that resistance-associated variants were highly associated with those patients not achieving SVR, and that the majority of patients with virologic BREAKTHROUGH or incomplete virologic response had viruses with detectable resistance-associated variants.
When analyzed as a function of poor response after the 4-week lead-in (less than 1-log10 viral load decrease) versus good response (greater than or equal to 1-log10 viral load decrease), resistance-associated variants were more frequent in patients with a poor lead-in response (68 percent) compared with patients with a good lead-in response (31 percent). Additional analyses are ongoing, with a 3.5-year long-term follow-up study underway to evaluate the persistence of resistance-associated variants over time."
Hector